Addendum
Tofacitinib (psoriatic arthritis) - Addendum to Commission A18-51
Report documents
-
Addendum
Tofacitinib (psoriatic arthritis) - Addendum to Commission A18-51
Dossier assessment
Indication:
Active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to a prior DMARD therapy
Result of dossier assessment:
Now hint of minor added benefit after pretreatment with a conventional synthetic DMARD. Added benefit still not proven after pretreatment with a biological DMARD
Additional information
Federal Joint Committee (G-BA)
2019-02-21 A G-BA decision was published.
Project details
- Project no.
- A19-03
- Commission
- Commission awarded on 07.01.2019 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Muscles, bones and joints
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Tofacitinib (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed